Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Zyla Life Sciences | a17-15599_3ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 5, 2017
Egalet Corporation
(Exact name of Registrant as specified in its charter)
Delaware |
|
001-36295 |
|
46-357334 |
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
600 Lee Road, Suite 100,
Wayne, Pennsylvania 19087
(610) 833-4200
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01 Other Events
Offering
On July 5, 2017, Egalet Corporation (the Company) issued a press release announcing its intention to offer and sell shares of its common stock and accompanying warrants in an underwritten public offering, subject to market conditions and other factors. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
At-The-Market Facility Sales
Pursuant to the Companys Controlled Equity OfferingSM Sales Agreement, dated July 2, 2015, with Cantor Fitzgerald & Co. during the second quarter of 2017, the Company sold an aggregate of 938,556 shares of common stock resulting in net proceeds of approximately $2.8 million.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 |
|
Press Release, dated July 5, 2017 |